Myeloma Paper of the Day, August 8th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Single center study confirms achieving MRD (Measurable residual disease)-negativity by NGS is linked to better outcomes in NDMM (newly diagnosed multiple myeloma) and RRMM (relapsed/refractory multiple myeloma), and high clonal diversity of IgH genes if MRD+ may be a (relatively) good prognostic sign also.”
Source: Robert Orlowski/X
Authors: Joaquín Martínez, Nieves López-Muñoz , Ajai Chari, Sara Dorado, Soraya Casla Barrio, Swaty Arora, Anupama Kumar, Alfred Chung, Thomas Martin and Jeffrey Wolf.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
